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ABSTRACT Despite recent advances in the therapeutic management of patients affected by pulmonary
arterial hypertension (PAH), survival remains poor. Prompt identification of the disease, especially in
subjects at increased risk of developing PAH, and prognostic stratification of patients are a necessary target
of clinical practice but remain challenging. Cardiopulmonary exercise test (CPET) parameters, particularly
peak oxygen uptake, end-tidal carbon dioxide tension and the minute ventilation/carbon dioxide
production relationship, emerged as new prognostic tools for PAH patients. Moreover, CPET provides a
comprehensive pathophysiological evaluation of patients’ exercise limitation and dyspnoea, which are the
main and early symptoms of the disease. This review focuses on the role of CPET in the management of
PAH patients, reporting guideline recommendations for CPET and discussing the pathophysiology of
exercise limitation and the most recent use of CPET in the diagnosis, prognosis and therapeutic targeting
of PAH.
Introduction
The cardiopulmonary exercise test (CPET) is a noninvasive method to assess functional capacity and exercise
limitation, providing information about the cardiovascular, respiratory, metabolic and muscular response
to physical effort. It can be recommended for all patients suffering from pulmonary hypertension (PH)
who are able to perform exercise testing and are clinically stable (New York Heart Association
(NYHA) functional groups I–III). Indeed, CPET is a safe test even in patients with severe exercise
limitation. As noted, it is a noninvasive method and is usually performed without assessment of arterial
blood gases. However, a differential diagnosis between group 1 (pulmonary arterial hypertension (PAH))
and group 3 (PH due to lung disease) might require an evaluation of changes in arterial carbon dioxide
tension (PaCO2) during exercise and in cardiac output (CO)/oxygen uptake (V′O2) ratio [1]. Nowadays,
CPET parameters, particularly peak V′O2, end-tidal carbon dioxide tension (PETCO2) and the minute
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ventilation (V′E)/carbon dioxide production (V′CO2) relationship (measured either as its ratio at the
anaerobic threshold (AT) or as its relationship slope) are considered to be of the utmost importance in the
diagnosis, prognosis and therapeutic management of PAH patients. However, all CPET-derived parameters
are underused even in major PH centres. This is likely due to a lack of expertise in the carrying out of
CPET and because, besides haemodynamic measurements, the functional class (which is based on
symptoms during exercise) and the six-minute walk test (6MWT) were historically considered enough to
stratify PAH risk and predict patients’ prognosis.
In this review we address the strengths and limitations of the use of CPET in PAH, focusing on pioneering
use, current and previous guidelines, physiological background and CPET use in PAH diagnosis and
prognosis.
The CPET in PAH: from experience to guidelines
PH is a progressive disease that leads to increased pulmonary arterial pressure (PAP) and pulmonary
vascular resistance (PVR) as well as to loss of pulmonary vasodilator response to exercise. The main and
early symptoms in PH are exercise intolerance and dyspnoea.
The clinical interest in PH is relatively recent and has developed in the last 40 years, starting after a
sudden increase in PH diagnosis in Switzerland, Germany and Austria in 1967 linked to the intake of
appetite-reducing drugs. The First World Symposium on Pulmonary Hypertension [2], which took place
in Switzerland in 1973, proposed the first definition of primary pulmonary hypertension (PPH; PH of
unknown cause) and secondary PH (PH of known cause), focusing basically on the epidemiologic and
pathophysiological features of the disease since no specific therapy was available. In the 1990s,
epoprostenol was the first PH-specific drug that was demonstrated to prolong survival and improve
functional capacity, assessed as distance walked, in PPH patients [3, 4]. Therefore, starting from World
Symposium on Primary Pulmonary Hypertension in Evian (1998) and carrying on during the world
symposia on PH held in Venice (2003), Dana Point (2009) and Nice (2013), the guidelines were revised
and the PH classification system improved, identifying four different categories sharing similarities in
pathophysiological mechanisms, clinical presentation and therapeutic options. Indeed, a few specific
therapies were approved simultaneously in the 2000s for the first group of the classification system, namely
PAH [5–8].
The first trials mainly included patients with severe PAH and they demonstrated that haemodynamic data,
functional class and the 6MWT were able to predict mortality and response to treatment [9–11]. For these
reasons and thanks to the simplicity of execution for both patients and physicians, the 6MWT has been
and remains until now the only exercise endpoint accepted by the Food and Drug Administration and the
European Agency for the Evaluation of Medicinal Products for studies evaluating treatment effects in
PAH, even if it has been demonstrated that the change in distance walked does not correlate with survival
or clinical events such as hospitalisations or need for rescue therapy [12]. Results from the STRIDE-1 trial,
the first and only trial that used both 6MWT and CPET as endpoints, were also against the use of
CPET-derived parameters for PAH evaluation [13]. Indeed, the study drug, sitaxentan, significantly
improved the 6MWT distance but not peak V′O2 [13]. Moreover, the 6MWT and CPET parameters were
not correlated, with the lack of sufficient expertise and accepted standardisation methods in performing
exercise tests in PH patients being suggested as the main reasons for this unexpected discrepancy [14].
Indeed, OUDIZ et al. [14] showed that the correlation between the 6MWT and CPET measurements
improved significantly as the study progressed, as did technical skills at less-experienced sites (where
ability increased over time). A further important reason for discrepancy in the STRIDE study lies in
considering the 6MWT unadjusted for body weight. Indeed, by taking into account patients’ body size,
OUDIZ et al. [14] were able to show an increased correlation between 6MWT and CPET.
All these observations confirm the need for quality-controlled CPET, as reported in guidelines starting
from 2009 [7]. However, in contrast to 6MWT that provides only limited clinical information, CPET has
the power to reveal the underlying pathophysiological consequences of the disease process and, in recent
years, several CPET variables have been recognised to be consistently altered in patients with PAH [15, 16].
Thus, 6MWT should be considered as complementary to CPET and not a replacement for it according to
the American Thoracic Society (ATS) [17]. Specifically, WENSEL et al. [18] found, in 70 patients affected by
idiopathic PAH, that systolic blood pressure at peak exercise, peak V′O2, exercise duration, PETCO2 at rest,
V′E/V′CO2 slope, diastolic blood pressure at peak exercise and heart rate (HR) at peak exercise predicted
survival. Moreover, on multivariate analysis, peak V′O2 and systolic blood pressure were independent
predictors of survival, while haemodynamic parameters were not independently predictive of mortality.
Starting from these data, the Dana Point guidelines reported the use of peak V′O2 as a prognostic tool in
the follow-up of PAH patients, particularly younger patients who are likely able to walk more than 500 m
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despite the presence of severe PAH and right ventricular (RV) dysfunction [7]. In these patients, 6MWT is
expected to be a submaximal test and, therefore, the additional exercise testing with CPET is particularly
useful in order to obtain a more reliable assessment of functional status and RV function. In the most
recent guidelines [19], a typical ventilatory pattern with low PETCO2 and high V′E/V′CO2 is also highlighted
and V′E/V′CO2 slope is included in the risk assessment of PAH patients with cut-off values based on
expert opinion (table 1).
Physiology of exercise in PAH
The origin of exercise intolerance and the occurrence of dyspnoea in PAH patients may be attributable to
several pathophysiological mechanisms [20]. First, during exercise, CO should rise to meet the increased
demand for oxygen by peripheral muscles. However, in patients with pulmonary vascular disease, CO fails
to increase during exercise due to a further rise in mean pulmonary arterial pressure (mPAP) and RV
failure, with consequent inadequate tissue oxygen delivery and thus the generation of early lactic acidosis
[15, 21, 22]. In a recent pilot study on invasive exercise haemodynamics, LADOR et al. [23] reported the CO
kinetics at the onset of exercise in PAH patients. The cardiac adaptation to exercise appeared to be slower
in PAH patients than in controls, with a decrease in CO at the onset of exercise due to a transitory
decrease in stroke volume, probably related to increased venous return and consequent worsening RV
function. Moreover, during effort, no significant increase in stroke volume was observed, indicating that
the increase in CO during exercise was attributable to the increase in HR. In the setting of CO assessment
in PH, both pre-capillary and post-capillary, FARINA et al. [24] reported an overall agreement among CO
determination by thermodilution, the direct Fick method and the inert gas rebreathing technique (Innocor
Rebreathing System, Innovision A/S, Odense, Denmark) in patients with PH without significant arterial
hypoxaemia, suggesting the possibility of a noninvasive and better-tolerated haemodynamic follow-up in
these patients. Unfortunately, reliable data on noninvasive assessment of exercise CO are presently lacking.
Secondly, abnormalities in arterial blood gases also play a role in exercise intolerance. In PAH,
mild-to-moderate arterial hypoxaemia and arterial hypocapnia are due to a combination of low mixed
venous oxygen saturation, high physiologic dead space, low alveolar–arterial diffusion and right-to-left
shunt through either a patent foramen ovale or intrapulmonary shunt. Hypoxaemia exacerbates the early
occurrence of lactic acidosis and stimulates the carotid bodies to augment the ventilatory drive,
contributing to an excessive increase in V′E during exercise [25]. In any case, the increased ventilatory
response to physical activity is associated with a reduced perfusion of well-ventilated alveoli. This
ventilation–perfusion mismatch causes high physiologic dead space (VD) to tidal volume (VT) ratio, or
inefficient ventilation, reflected in a high V′E/V′CO2 ratio measurable both as V′E/V′CO2 at a given exercise
level or as the slope of the V′E/V′CO2 relationship [26]. The two possible behaviours of the V′E/V′CO2
relationship are reported in figure 1. In figure 1a, hyperventilation did not influence the physiological
domains of V′E during exercise and these are thus maintained such that the characteristic slopes of the V′E
versus V′CO2 relationship can be appreciated. In figure 1b, the ventilatory stimuli are so strong as to
overwhelm normal physiology, such that a single slope characterises the V′E/V′CO2 relationship. The
increase in V′E/V′CO2 slope is paralleled by an increase in dead space ventilation during exercise. This is
approximately one third of V′E, a value much higher when compared to healthy subjects, in whom dead
space V′E physiologically declines during exercise [27, 28]. The increase of functional VD/VT and of
ventilation also leads to a reduction of PETCO2 at rest and to a further decrease during exercise. Low
PETCO2 is related to ventilatory inefficiency, which causes the dilution of PETCO2 relative to PaCO2.
Furthermore, PETCO2 reduction is proportional to peak V′O2 impairment and inversely correlated with the
elevation in mPAP [29]. The arterial to end-tidal carbon dioxide tension difference (Pa-ETCO2), a reflection
of ventilation–perfusion inequality, is positive at rest and increases in patients with PAH, whereas,
in healthy people, Pa-ETCO2 is reduced and often negative at peak exercise [30]. Another feature is the
dynamic hyperinflation observed in 60% of PH patients studied by LAVENEZIANA et al. [31]. This paper is
TABLE 1 Cardiopulmonary exercise test (CPET) determinants of prognosis in risk assessment
CPET parameters Low Risk (<5%) Intermediate risk (5–10%) High risk (>10%)
Peak V′O2 mL·kg−1·min−1 >15 11–15 <11
Peak V′O2 % predicted >65 65–35 <35
V′E/V′CO2 slope <36 36–45 >45
V′O2: oxygen uptake; V′E : minute ventilation; V′CO2: carbon dioxide production; V′E/V′CO2 slope: slope of the
relationship between V′E and V′CO2.
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interesting not only because of the Pa-ETCO2 concept but also because of the respiratory mechanic
abnormalities assessment by inspiratory capacity manoeuvres. In this respect, the visual inspection of the
V′E/V′CO2 relationship gives a lot of information (figure 2). Indeed, the slope is high and the V′E-axis
intercept (i.e. when V′CO2=0) is often close to zero or negative. This means that dead space V′E increases
progressively during exercise. Notably, when two linear segments are identified on the V′E/V′CO2
relationship plot, the second has a very high slope and a severely negative V′E-axis intercept, showing that
the increase of dead space V′E pertains specifically to the last part of exercise.
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FIGURE 1 The minute ventilation (V′E)/carbon dioxide production (V′CO2) relationship slope in two pulmonary
arterial hypertension patients. In (a) the physiological behaviour of ventilation during exercise is preserved in
spite of hyperventilation, such that two slopes can be recognised around the respiratory compensation (RC)
point (slope 1 (S1)=40.4 and slope 2 (S2)=55.1). In (b) a single slope characterises the V′E/V′CO2 relationship.
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FIGURE 2 The minute ventilation (V′E)/carbon dioxide production (V′CO2) relationship slope in a patient with
pulmonary arterial hypertension and preserved physiological behaviour of the V′E/V′CO2 relationship during
exercise. In the first part of exercise, the V′E/V′CO2 slope is high and the V′E-axis intercept is close to zero. This
means that dead space ventilation progressively increases during exercise. After the end of isocapnic
buffering, i.e. at the respiratory compensation (RC) point, the slope becomes steeper and the V′E-axis
intercept becomes severely negative showing that dead space ventilation severely increases toward the end of
exercise. Reproduced from [32] with permission.
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Thirdly, an increase in chemosensitivity could also play a role in PAH hyperventilation. Indeed, severe
PAH leads to RV failure and consequently to low CO, which could activate a sympathetic response similar
to that described in left-ventricular failure. Additionally, the further augmentation of catecholamines,
arterial potassium level elevation, progressive lactacidemia, enhanced RV distension, higher pulmonary
intra-vascular pressures, hypoxaemia and increased oscillations in pH may also contribute to increased
chemoreflex activity during exercise [33]. Indeed, only very recently FARINA et al. [28] demonstrated an
increase in chemosensitivity for oxygen and carbon dioxide. Specifically, the central carbon dioxide
chemoreceptor presented a direct correlation with alveolar V′E, suggesting a preserved role for central
chemoreceptor activity and alveolar V′E increase during exercise. Notably, functional hypercapnic
chemosensitivity is predominantly mediated by the central chemoreceptors, while peripheral hypercapnic
chemosensitivity accounts for only one tenth of the overall carbon dioxide chemosensitivity [34]. However,
the mechanisms which cause altered chemosensitivity are unclear. Indeed, besides the traditionally
recognised stimuli such as low partial pressure of oxygen (PO2), high partial pressure of carbon dioxide
(PCO2) and unbuffered acidosis, a direct role for lactic acid on peripheral chemoreflex activity and
chemoreflex stimulation has been suggested [35, 36].
Finally, respiratory and peripheral muscle impairment and fatigue could also contribute to exercise
intolerance. Peripheral muscle dysfunction in PAH is related to low CO, vasoconstriction and deconditioning,
but it may also be due to altered skeletal muscle microcirculation [37]. LAVENEZIANA et al. [31] showed that
PAH patients have preserved inspiratory muscle function regardless of changes in dynamic inspiratory
capacity during cycle exercise and that the inspiratory capacity manoeuvre is reliable in evaluating
dynamic hyperinflation during CPET in PAH. Metabo-reflexes likely contribute to exercise-induced
hyperventilation in PAH, as is the case in patients with left-heart failure [38]; however, this has only very
recently been shown in PAH [24].
The use of the CPET in the diagnosis of PAH
CPET is useful to support the diagnosis of PAH both in patients with dyspnoea of unknown aetiology and
in patients with symptoms, signs, history and echocardiographic findings suggestive of PH, allowing the
identification of typical cardiac and ventilatory patterns during exercise. Moreover, in the diagnostic
process, CPET is suitable for establishing and guiding therapeutic management [19, 39] and it has recently
been demonstrated to be predictive of haemodynamic findings [40]. The CPET parameters associated with
PAH are reported in table 2.
CPET parameters become progressively more impaired as pulmonary pressure increases and PAH worsens
from mild to severe [41]. In a retrospective analysis of 53 patients, SUN et al. [20] described the exercise
pathophysiology of PAH, showing that the typical CPET pattern is characterised by a moderate to severe
reduction in peak V′O2 and work rate (WR), accompanied by a cardiovascular impairment, a respiratory
impairment and a pulmonary vascular impairment. In fact, in these patients, a reduction of oxygen pulse,
AT and the V′O2/WR relationship, as well as a marked increase of the V′E/V′CO2 slope and of the VD/VT
ratio are commonly observed (table 3). For this last setting in particular, blood gas analysis should be
performed during exercise to allow an accurate assessment of oxygen saturation and correct calculation of
VD/VT. In fact, the noninvasive estimation of PaCO2 (and hence of VD/VT) from PETCO2, using the
equations from JONES et al. [30], does not work in patients with PAH. Thus, real blood gas measurements
TABLE 2 Common cardiopulmonary exercise test findings in patients with pulmonary arterial
hypertension
Reduced parameters Increased parameters
Peak V′O2 VD/VT during exercise (>30%)
WR PA–aO2 differences during exercise
(up to 45 mmHg or over)
O2 pulse
V′O2/WR
PETCO2 at rest
PETCO2 at AT
O2 saturation during exercise
(drop >3% without PaCO2 rise)
V′O2: oxygen uptake; VD: dead space volume; VT: tidal volume; WR: work rate; PA–aO2: alveolar–arterial
oxygen tension difference; PETCO2: end-tidal carbon dioxide tension; AT: anaerobic threshold; PaCO2: arterial
carbon dioxide tension.
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at exercise are necessary to calculate VD/VT [42]. A VD/VT increase of >30% during exercise indicates the
presence of pulmonary vascular limitation and is associated with an increase in alveolar–arterial gradient
(to 45 mmHg or more) caused by V′E/perfusion mismatch and by low alveolar–capillary gas diffusion. In
a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed,
besides a low stroke volume, a low arterial–venous oxygen difference (due to hypoxia-related low arterial
oxygen content) also plays a major role. However, inert gas studies suggest that hypoxaemia during
exercise in PAH is explained by low mixed venous oxygen and high mean V′E/perfusion even without
impaired gas diffusion [43].
Peak V′O2 describes the presence of a functional impairment and its absolute or % predicted value is used
to grade the severity of exercise limitation in patients affected by cardiac diseases. Peak V′O2 correlates well
with NYHA class in PAH patients. The kinetics of V′O2 increase during unloaded cycling exercise are
impaired in this population, as demonstrated by an increase in mean response time (MRT), indicating a
less efficient coupling of oxygen delivery and uptake [20]. Low peak V′O2 alone is not sufficient to suggest
the diagnosis of PAH; however, the combination of an increase in V′E/V′CO2 slope with reduced values of
PETCO2 has high diagnostic accuracy, identifying the likelihood of pulmonary vasculopathy in patients with
exertional dyspnoea of unknown origin and in those with echocardiographic findings of suspected PAH
(as demonstrated by the groups of WASSERMAN and PALANGE using a cycle ergometer and a treadmill,
respectively [20, 26]). YASUNOBU et al. [29] have described specific PETCO2 kinetics (in 52 PAH patients)
with reduced PETCO2 at rest, a further decrease during exercise up to the peak and abnormally low PETCO2
values in any given exercise phase. Moreover, the authors demonstrated that the combined analysis of
PETCO2 and V′E/V′CO2 ratio at AT can classify the suspicion of PAH in unlikely, suspect, likely, or very
likely subjects and is able to guide physicians to further evaluations to confirm the diagnosis. If PETCO2 at
AT is <30 mmHg, PAH should be considered as a possible diagnosis; however, if it is <20 mmHg, the
likelihood of PAH is even higher since these values are unusual in other clinical conditions [29]. More
recently, ZHAO et al. [44] demonstrated that by combining V′E/V′CO2 slope and AT with an
echocardiographic evaluation, an increase in the diagnostic specificity for PAH can be reached. In this
study, 88 patients with a Doppler-estimated systolic PAP of 37–50 mmHg by echocardiography (or
<36 mmHg in the presence of additional echocardiographic variables suggestive of PAH) were evaluated
TABLE 3 Resting and exercise values in normal subjects and primary pulmonary hypertension
(PPH) patients categorised according to severity of reduction in cardiopulmonary exercise test
(CPET) aerobic capacity
Values Normal#
(n=20)
Mild PPH
(n=3)
Moderate PPH
(n=14)
Severe PPH
(n=22)
Very Severe
PPH (n=14)
Peak V′O2 % predicted range 82–132 65–79 50–64 35–49 <35
Peak V′O2 % predicted 101±19 70±4 58±4 42±5 27±4
Peak V′O2 mL·min−1·kg−1 29.5±6.6 14.5±3.3 12.5±2.2 11.2±2.6 8.1±1.7
AT % predicted 104±16 85±7 75±10 57±9 41±7
AT mL·min−1·kg−1 16.3±3.9 10.4±2.3 9.7±1.3 8.7±2.2 6.8±1.3
Peak O2 pulse % predicted 108±25 86±11 73±8 56±11 39±5
Peak HR % predicted 96±13 83±12 80±8 77±12 70±13
ΔV′O2/ΔWR mL·min−1·W−1 9.6±0.9 8.3±0.5 7.0±1.5 6.0±1.0 5.6±1.3
V′E/V′CO2 at AT % predicted 99±12 142±22 149±21 161±25 219±76
V′E/V′CO2 at AT absolute 29±4 43±6 45±7 46±8 62±20
V′E/V′CO2 slope % predicted 88±11 164±49 148±27 141±32 215±123
V′E/V′CO2 slope absolute 25±3 49±14 45±9 40±10 60±32
Peak V′E % MVV 70±15 63±19 54±9 47±11 43±16
MRT s 12±10 34±9 37±14 47±13 64±15
mPAP mmHg 48±17 63±14 70±18 57±17
CO L min−1 5.1±1.1 4.4±1.4 3.5±1.0 3.8±1.2
PVR mmHg·L−1·min−1 8±4 15±8 18±5 14±6
NYHA symptom class 2.0±0.4 2.5±0.5 2.8±0.6 3.3±0.4
V′O2: oxygen uptake; AT: anaerobic threshold; HR: heart rate; WR: work rate; V′E: minute ventilation; V′CO2:
carbon dioxide production; MVV: maximum voluntary ventilation; MRT: mean response time of V′O2 during
unloaded cycling; mPAP: mean pulmonary arterial pressure; CO: cardiac output; PVR: pulmonary vascular
resistance; NYHA: New York Heart Association; V′E/V′CO2 slope: slope of the relationship between V′E and
V′CO2; V′E/V′CO2 at AT: ratio of ventilation to carbon dioxide output at AT; ΔV′O2/ΔWR: increase in oxygen
uptake per increase in work rate. #: each CPET parameter is significantly different for all PPH patients
compared to that of normal control subjects (p<0.001). Data is reproduced from [20] with permission.
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retrospectively. Compared to non-PAH patients, PAH subjects showed lower peak V′O2 and anticipated
AT, higher V′E/V′CO2 slope and lower PETCO2 values. Moreover, they found that the combination of V′E/V
′CO2 slope and AT led to a specificity of 95% and a sensitivity of 92.6% for the identification of PAH.
In addition to these parameters, PAH patients usually experience a decrease in oxygen saturation from rest to
peak exercise of >3% without a rise in PaCO2, which has been recognised for many years as a major criterion
of pulmonary vascular exercise limitation [45]. This behaviour is commonly found in subjects with moderate,
severe and very severe impaired PAH, and this reduction is proportional to the severity of the disease. The
presence of desaturation is also related to the opening of a right-to-left exercise-induced shunt. PAH patients
with shunt show the lowest values of PETCO2 at rest. In this regard, it is of note that when an abrupt decrease
of PETCO2 and an abrupt increase of end-tidal oxygen tension (PETO2), V′E/V′O2 and respiratory exchange
ratio are observed during exercise, followed by a reduction in oxygen saturation, the beginning of a
right-to-left shunt possibly due to the opening of a patent foramen ovale must be suspected [46].
Regarding emerging CPET variables, PAH patients exhibit low values of the oxygen uptake efficiency
(OUE) plateau (calculated as the 90 s average of the highest consecutive measurements of V′O2/V′E near
AT) and the OUE slope (calculated as the regression slope “a” in V′O2=a×log10V′E+b), indicating
ventilatory inefficiency during exercise [47] (figure 3). TAN et al. [48] compared 32 patients with idiopathic
PAH to 16 controls and showed that OUE slope and OUE plateau were significantly lower and the V′E/V
′CO2 slope was significantly higher in the former. Similarly, the study by ZHAO et al. [44] mentioned above
showed a reduction of OUE slope and OUE plateau in patients with a suspicion of PH that accompanies
the already mentioned typical CPET pattern observed in this population. These parameters are promising
variables in the diagnostic management of PAH patients; however, more data are needed to confirm these
initial findings.
The use of the CPET for prognostication in PAH
Right-heart catheterisation remains the gold standard to confirm a diagnosis of PAH. Some CPET
parameters can predict or sometimes confirm the vascular disease pattern but they cannot confirm a
diagnosis of PAH. In fact, CPET sometimes provides an indication for right-heart catheterisation.
However, CPET can provide important prognostic information regarding patients with pulmonary diseases
[26]. Exercise variables, such as peak V′O2, V′E/V′CO2 and arterial oxygen saturation (SaO2) are able to
better predict prognosis than resting lung function measurements. A number of CPET variables have been
shown to be consistently altered in patients with PAH and they play a role in prognostic stratification in
both PAH and chronic thromboembolic pulmonary hypertension (CTEPH) [49]. However, although most
of these variables provide prognostic information, peak V′O2 is most widely used for therapeutic decision
making [18, 41, 50, 51].
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between a typical pulmonary arterial hypertension (PAH) patient and a “normal” control subject. In normal
subjects, OUE typically increases during exercise from rest to plateau and then gradually decreases until the
end of exercise. It then further decreases in the immediate recovery period and begins stabilising after about
2 min. In PAH patients, OUE changes in a similar way to control subjects but is always lower than in controls
in the transition from rest to the end of exercise. Reproduced from [48] with permission.
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It should be noticed that, although treatment advances in the last two decades have improved symptoms
and survival of patients with PAH, prognosis remains poor and individual risk stratification is still of
major importance. Therefore, it is mandatory to establish the appropriate treatment strategy and a mild
approach with oral drugs or a more aggressive approach including parenteral prostanoids are both
considered in international guidelines based on risk assessment [19]. However, how to translate into
clinical practice the multiparametric approach to risk stratification proposed by current guidelines is still
unclear. Further studies on PAH are needed to allow for a more comprehensive, definite and documented
integration of CPET into the guidelines list of “variables to consider for severity assessment”, which, at
present, only mentions expert opinion values for peak V′O2 and V′E/V′CO2 [19]. Indeed, more robust
prognostic evidence for peak V′O2 and V′E/V′CO2 arises from the studies by WENSEL et al. [50] and
DEBOECK et al. [52], both powered for multivariate analysis in a modern treatment context, although the
added value of CPET on top of common clinical and haemodynamic variables remains unexplored.
Recently, however, BADAGLIACCA et al. [53] documented the increased power of a risk prediction model
considering oxygen pulse and echocardiographically-determined RV systolic function compared to the
traditional model including clinical, invasive haemodynamic and 6MWT variables. Indeed, a combination
of low RV fractional area change and low oxygen pulse might identify patients at a particularly high risk
of clinical deterioration.
The 6MWT is the most used test to predict survival in PAH patients and, in order to assess whether
CPET adds prognostic value to the information derived from 6MWT, it has been demonstrated that CPET
parameters predict survival in PAH patients and add information to the prognostic value of 6MWT [54].
For example, after multivariable Cox regression, reduction in SaO2 during exercise significantly improved
the univariate 6MWT prediction model. SCHWAIBLMAIR et al. [49] determined ventilatory efficiency in PAH
and chronic thromboembolic PAH patients through CPET, identifying PAH patients with increased risk of
death within 24 months from evaluation. The authors showed significant differences between survivors
and non-survivors in ventilatory equivalents for oxygen (42.1±2.1 versus 56.9±2.6; p<0.005) and for carbon
dioxide (47.5±2.2 versus 64.4±2.3; p<0.005). Patients with peak oxygen uptake ⩽10.4 mL·min−1·kg−1 had a
1.5-fold higher risk of mortality in the following 24 months. The risk was 7.8-fold higher with a V′E/V′CO2
ratio at AT ⩾55, 2.9-fold higher with an alveolar–arterial oxygen difference ⩾55 mmHg and 5.8-fold
higher with a V′E/V′CO2 slope ⩾60.
There are different considerations about the prognostic role of CPET in the treatment of PAH.
GROEPENHOFF et al. [55] showed that survivors had a significantly greater change in peak V′O2 than
nonsurvivors and this change in aerobic capacity was significantly related to changes in right ventricular
ejection fraction (RVEF). Notably, treatment-associated changes in V′O2 and oxygen pulse predicted
survival, whereas changes in V′E/V′CO2 slope did not.
In addition, the combined use of peak V′O2 and PVR provides accurate risk stratification underlining the
important and complementary prognostic information from cardiopulmonary exercise testing and resting
invasive haemodynamic data [50]. These different approaches may be complementary in the risk
stratification of PAH patients and exercise haemodynamic data has been correlated with peak V′O2 [56] to
determine their prognostic significance. This has shown that exercise cardiac index correlates with peak V
′O2 and is the only independent predictor of peak V′O2 on multivariate stepwise linear regression analyses.
Furthermore, peak V′O2 is the strongest predictor of survival in this analysis.
FERREIRA et al. [57] have demonstrated that, considering all data points, measurements of excessive exercise
V′E might improve the usefulness of incremental CPET in the prognostic evaluation of PAH. OUE slope
may also be a useful noninvasive marker of disease severity and outcome in paediatric patients [58].
Indeed, it has been demonstrated that ventilatory efficiency slope in children and young adults with a
diagnosis of PAH and poor outcomes (nine deaths, three lung transplants) is significantly elevated
compared to patients with better outcomes (51.1 versus 37.9; p<0.001). Moreover, the persistence or
development of an exercise-induced right-to-left shunt strongly predicts death or transplantation in PAH
patients, irrespectively of the haemodynamics and all other exercise measures including peak V′O2 and
OUE slope. Furthermore, a poorer OUE slope appears to be associated with a poor outcome in patients
without a shunt. So, a persistent exercise-induced right-to-left shunt and poor ventilatory efficiency are
highly predictive of poor outcomes in patients with PAH [59].
Another possible prognostic CPET-derived variable is the delayed post-exercise HR recovery (1 min)
response [60], which is reportedly much lower in PH patients than in controls. The best cut-off for HR
recovery in 1 min to discriminate between patients and controls is 18 beats. Patients with HR recovery
(1 min) >18 had better NYHA scores, resting haemodynamics and 6MWT distance. On a multiple
regression analysis that only considered CPET-independent variables, HR recovery (1 min) ⩽18 was the
only predictor of mortality [60].
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Conclusions
Today CPET is utilised for PH evaluation in only a few centres with expertise in the technique and there
are currently very few data on the prognostic importance of treatment-induced changes in CPET variables.
These preliminary results need to be confirmed in larger cohorts of patients and in a properly powered
multicentric study. Furthermore, only an extensive use of CPET can confirm its role in the clinical
assessment of PAH and provide a cost/effectiveness evaluation. The utility of CPET data from centres that
seldom perform the technique or that are not specialised in the evaluation of PAH cases remains
controversial.
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